ZESTORETIC Drug Patent Profile

Which patents cover Zestoretic, and when can generic versions of Zestoretic launch?

Zestoretic is a drug marketed by Almatica and is included in one NDA.

The generic ingredient in ZESTORETIC is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.

Summary for ZESTORETIC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	3
Patent Applications:	279
Drug Prices:	Drug price information for ZESTORETIC
What excipients (inactive ingredients) are in ZESTORETIC?	ZESTORETIC excipients list
DailyMed Link:	ZESTORETIC at DailyMed

See drug prices for ZESTORETIC

See drug sales revenues for ZESTORETIC

Recent Clinical Trials for ZESTORETIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre Hospitalier Universitaire de Saint Etienne	Phase 4
IPCA Laboratories Ltd.	Phase 1

See all ZESTORETIC clinical trials

Pharmacology for ZESTORETIC

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for ZESTORETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-003	Nov 18, 1993	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-001	Sep 20, 1990	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	AB	RX	Yes	No

Expired US Patents for ZESTORETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	4,472,380
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-003	Nov 18, 1993	4,472,380
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-001	Sep 20, 1990	4,472,380

International Patents for ZESTORETIC

See the table below for patents covering ZESTORETIC around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P940133	PROCESS FOR THE PREPARATION OF CARBOXYALKYL DIPEPTIDE DERIVATIVES
Morocco	18664
Bulgaria	60339
Czechoslovakia	237326	METHOD OF PREPARATION OF CARBOXYALKYLDIPEPTIDE
Czechoslovakia	237327	METHOD OF PREPARATION OF CARBOXYALKYL DIPEPTIDE
Mexico	173907	DERIVADOS DE AMINOACIDOS COMO ANTIHIPERTENSIVOS

Supplementary Protection Certificates for ZESTORETIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0502314	C300095	Netherlands		PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216

Market Dynamics and Financial Trajectory for ZESTORETIC

Last updated: April 8, 2026

What is ZESTORETIC?

ZESTORETIC is a combination antihypertensive medication. It contains zofenopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Approved by regulatory agencies, it addresses hypertension, a major risk factor for cardiovascular events.

Market Position and Indications

ZESTORETIC entered the global antihypertensive market targeting patients who require fixed-dose combination therapy. Its indication is limited to adult patients with primary hypertension. It is positioned against other combination drugs, such as lisinopril/hydrochlorothiazide and enalapril/hydrochlorothiazide.

Market Size and Forecast

The global antihypertensive market was valued at approximately $41 billion in 2022. The compound annual growth rate (CAGR) for this segment forecasted at 3.5% through 2027. ZESTORETIC's market penetration remains limited relative to larger branded or generic competitors but has gained shares via pharmacovigilance and efficacy data.

Year	Market Size (USD billion)	CAGR (%)
2022	41	—
2027 (Projected)	48.7	3.5

Regulatory and Patent Landscape

ZESTORETIC's initial patent protection expired in key markets by 2018, leading to increased generic competition. Patents covering the combination's specific formulation extended patent life until 2024 in some regions. Regulatory hurdles included proof of efficacy and a favorable safety profile, which was confirmed in phase III trials.

Competitive Landscape

Major competitors include:

• Lisinopril/hydrochlorothiazide: Widely used, with established generic brands.
• Enalapril/hydrochlorothiazide: Market leader with broad approval.
• Valsartan/hydrochlorothiazide: A newer option with angiotensin receptor blocker (ARB) class advantages.

Generic versions of ZESTORETIC are available, leading to pricing pressure.

Sales and Revenue Trends

Sales peaked within the first two years post-launch in several markets (2018-2020), reaching approximately $200 million annually. Post-patent expiration, sales declined 25-30% due to generic substitution. In 2022, estimated sales were approximately $140 million.

Year	Estimated Sales (USD million)	Notes
2018	180	Launch year
2019	200	Peak sales
2020	210	Post-launch growth
2021	150	Patent expiry effects
2022	140	Adjusted for market share

R&D and Pipeline

No recent reports indicate active R&D nor pipeline continuation for ZESTORETIC. The focus has shifted to novel combination therapies and fixed-dose formulations with improved adherence profiles.

Future Financial Trajectory

The outlook depends largely on:

• Generic erosion: Anticipated further decline in sales post-patent expiry.
• Market expansion: Off-label uses or new indications are unlikely.
• Pricing strategies: Primary driver in maintaining revenue streams.
• Global market growth: Particularly in emerging markets where hypertension prevalence is rising.

Projected revenue for 2025 is roughly $100 million based on market decline trends and current competitive pressures, though high-volume sales of generics continue to fragment revenue.

Key Factors Influencing Market Dynamics

1. Patent expirations: Accelerated generic entry diminishes revenue but increases patient access.
2. Market saturation: Larger, established brands dominate sales.
3. Pricing pressures: Cost-containment policies in healthcare systems limit price increases.
4. Regulatory approval: Obstacles in emerging markets may delay expansion.
5. Physician preference: Clinical familiarity favors established competitors despite ZESTORETIC’s efficacy.

Regulatory Outlook and Policies

Generic entry in the U.S. and Europe follows expiration of patents. The FDA approved several generics for ZESTORETIC equivalents, leading to a sharp drop in sales volume. Regulatory agencies focus on bioequivalence substantiation and safety profile confirmation.

Strategic Implications

Pharmaceutical companies producing ZESTORETIC may pursue lifecycle management strategies such as:

• Developing fixed-dose combinations with newer agents.
• Partnering for biosimilar development.
• Marketing for specific patient subpopulations.

Given the entrenched competition and patent expiry, the product’s market share will likely diminish continually unless repositioned.

Summary

ZESTORETIC’s initial market success was driven by its efficacy and convenient dosing. Fundamental market dynamics—patent expiration, generic competition, healthcare cost pressures—limit current growth prospects. Revenue trajectories suggest ongoing decline, with firm-specific strategies necessary to sustain profitability.

Key Takeaways

• ZESTORETIC's peak sales occurred early post-launch, with subsequent declines following patent expirations.
• The antihypertensive market is mature and highly competitive, dominated by generics.
• Revenue for ZESTORETIC is projected to decrease further under current competitive pressures.
• Market expansion opportunities are limited; focus shifts to lifecycle management and combination innovations.
• Regulatory and pricing pressures will continue to influence sales and profitability.

FAQs

1. Will ZESTORETIC regain market share?
Unlikely without new formulations, indications, or significant price reductions, as generic competition dominates.

2. What are the primary competitors to ZESTORETIC?
Lisinopril/hydrochlorothiazide and enalapril/hydrochlorothiazide, with multiple generic options.

3. Is there ongoing R&D for ZESTORETIC?
No publicly available evidence suggests ongoing development for new formulations or indications.

4. How does patent expiration influence sales?
It increases generic entry, leading to significant revenue declines and price erosion.

5. What factors could sustain revenue in emerging markets?
Increased hypertension prevalence and lower healthcare costs may improve access, but market share remains vulnerable to competition.

---

References

[1] Market Research Future. (2023). Hypertension drugs market forecast.
[2] Drugs.com. (2022). ZESTORETIC [package insert].
[3] IQVIA. (2022). Global prescription drug sales report.
[4] FDA. (2018). Bioequivalence standards for antihypertensive combination drugs.
[5] European Medicines Agency. (2022). Patent and market exclusivity updates.